Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

223.94 +4.05 (+1.84%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and...

Via MarketBeat

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention ↗

August 20, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation ↗

August 01, 2026

Via Chartmill

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗

September 19, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with...

Via MarketBeat

Topics Death

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Analysts think Alnylam could rebound strongly over the next 12 months.

Via The Motley Fool

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 15.67%. Currently, Alnylam Pharmaceuticals...

Via Benzinga

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on an annualized basis producing an average annual return of 15.09%. Currently, Alnylam Pharmaceuticals...

Via Benzinga

Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP

August 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP

August 20, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 19, 2026

From Kirby McInerney LLP

Via Business Wire

NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc.

August 19, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm

August 18, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 17, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Via The Motley Fool

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 14, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

August 10, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on an annualized basis producing an average annual return of 15.23%. Currently, Alnylam Pharmaceuticals...

Via Benzinga

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Alnylam (ALNY) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Via The Motley Fool

Topics Earnings

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 03, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Via The Motley Fool

Topics Earnings

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 30, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 30, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.